A 35-year-old male with severe atopic dermatitis (AD) saw partial improvement with dupilumab and halobetasol, leading to the addition of the JAK inhibitor tofacitinib. Although this combination cleared his AD, tofacitinib was discontinued due to risks and insurance issues, continuing treatment with only dupilumab. This case emphasizes the importance of risk evaluation and the promise of new JAK inhibitor developments.

Reference: Peterson DM, Vesely MD. Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy. JAAD Case Rep. 2021;10:4-7. doi:10.1016/j.jdcr.2021.01.020